New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

Eli Lilly's experimental GLP-1 pill, orforglipron, showed promising results in a late-stage trial, aiding weight loss by 10.5 ...

Eli Lilly's experimental pill, Orforglipron, helps overweight adults with type 2 diabetes lose 10.5% of their body weight in ...

Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant announced positive results from a Phase 3 trial of its oral weight loss pill, paving the way for ...

Eli Lilly (LLY) stock is up as the firm's oral weight loss drug orforglipron hits key goals in another Phase 3 trial, ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...

Using the Mediterranean diet, exercise and nutritional support, severely overweight people stopped their progression to type ...